Aprea Therapeutics Inc (NAS:APRE)
$ 5.8 -0.09 (-1.53%) Market Cap: 31.50 Mil Enterprise Value: 3.20 Mil PE Ratio: 0 PB Ratio: 1.30 GF Score: 42/100

Aprea Therapeutics Inc at 38th Annual J.P Morgan Healthcare Conference Transcript

Jan 14, 2020 / 11:30PM GMT
Release Date Price: $796.4 (+3.64%)
Jessica Macomber Fye
JP Morgan Chase & Co, Research Division - Analyst

Good afternoon. I'm Jess Fye, one of the biotech analysts at JPMorgan, and we're continuing the 2020 Healthcare Conference this afternoon with Aprea. We're going to do a quick Q&A session with the management team right after this presentation ends. It's going to be just down the hall in the Yorkshire room. But for the presentation, I'm going to turn it over to the company's CEO, Chris Schade.

Christian S. Schade
Aprea Therapeutics, Inc. - President, CEO & Director

Thank you, Jess, and thank you for JPMorgan for inviting us to the conference, and thank you all for attending the presentation today. What I'd like to do today is sort of give you an update of the considerable progress that Aprea is making in its own clinical program to advance the very first p53 reactivator into commercialization. So we've made considerable progress in this field in MDS, myeloid disease and AML, and we're now branching off into different disease indications as well. So today, we'll give you a good

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot